ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

AACI to coordinate clinical trials project.

October 17, 2003

Spending Freeze Could Harm Medical Research, ACS Advocacy Affiliate Says

January 29, 2010

ODAC Rejects Temodal for Melanoma After Discussion Of Approval Standards

April 2, 1999

NCI Shifts Money to Save 100 Training Slots

July 14, 1989

New Grant Program To Fund Partnerships Between Academia, Industry, Non-Profits

March 14, 2003

In Brief: Twenty-Nine Percent Of Approved Organ Systems Applications Funded In February, May Cycles

November 4, 1983